Search - tctmd.com

Displaying 21 - 40 of 53

Sort: Relevancy | Date

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

Todd Neale

December 22, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Opinion CV Team Dispatch

November 2023 News Roundup

L.A. McKeown

November 01, 2023

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

L.A. McKeown

October 18, 2023

News Daily News

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

L.A. McKeown

October 10, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

Medical Therapy ‘Disappointing’ Prior to TEER for Functional MR: TVT Registry

Michael O'Riordan

September 27, 2023

News Opinion CV Team Dispatch

September 2023 News Roundup

L.A. McKeown

September 01, 2023

News Conference News ESC Heart Failure 2023

SGLT2i Still Underprescribed in HFrEF, New US Analysis Confirms

L.A. McKeown

June 06, 2023

News Opinion CV Team Dispatch

May 2023 News Roundup

L.A. McKeown

May 01, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Opinion CV Team Dispatch

February 2023 News Roundup

L.A. McKeown

February 15, 2023

News Daily News

Top Heart Failure News of 2022

Shelley Wood

January 04, 2023

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

L.A. McKeown

October 07, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Conference News ESC Heart Failure 2022

Speech-Recognition Tool May Predict Worsening Congestion in HF

Shelley Wood

May 22, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Caitlin E. Cox

April 15, 2022

Advertisement

May 2024 Dispatch for the CV Team

AHA Selects 2023’s Leading Cardiovascular Research

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 2023 News Roundup

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

FDA Decides Not to Approve Patisiran in ATTR Cardiomyopathy

October 2023 News Roundup

Medical Therapy ‘Disappointing’ Prior to TEER for Functional MR: TVT Registry

September 2023 News Roundup

SGLT2i Still Underprescribed in HFrEF, New US Analysis Confirms

May 2023 News Roundup

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

February 2023 News Roundup

Top Heart Failure News of 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Speech-Recognition Tool May Predict Worsening Congestion in HF

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content